Peptalk 2008 The Definitive Protein Focused Event
会议概要 短期研讨会 会议议程 展示者/赞助厂商 地点 询问 报名   Hotel Del Coronado / San Diego, California
Alternate Language Options:
Japanese Korean Traditional Chinese English

Download Brochure
PDF (English): Catalog

PDF (English): Schedule

GEN

Additional Media Partners


Insight Pharma Reports产业/市场情报数据
Insight Pharma Reports

冻结乾燥会议 - Day 3

概要 | Day 1 | Day 2 | Day 3

议程 (PDF : English)

DAY THREE
Friday, January 11, 2008

7:30 am - 4:00 pm Registration Open

7:30 am - 8:15 am Breakfast Workshop or Morning Coffee

8:15 Chairperson乫s Remarks 

8:20 Moisture Content in Freeze-Dried Product
Yves Mayeresse, Ph.D., Senior Manager, Head of Freeze-Drying, GlaxoSmithKline Biologicals (Belgium)

Moisture content is one of the major output parameters for freeze-dried product. The presentation first reviews sorption and desorption isotherm. An evaluation and validation of moisture limit for a freeze-dried product is then proposed. The different available tools to analyze moisture content inside freeze-died product are described. An evaluation of different lyoprotectors is done. Their evolution during shelf life using non destructive methods is performed. The relevant factors influencing final moisture content during secondary drying of the freeze-drying cycle are evaluated. Finally a simple theoretical model to explain the different results obtained will be described. Attendees will learn:

  • A Better understanding of key parameters influencing the freeze-drying process
  • A realistic expectation in terms of moisture content in regard of the formulation
  • The different tools allowing to follow moisture content for freeze-dried product
8:50 Points to Consider on Freeze Drying Process Design for Scale-Up
Charlie Tang, Ph.D., Sr. Research Scientist, Formulation Development, Centocor, Inc. (J&J)
Manometric Temperature Measurement (MTM) yields data of product temperature and dry cake resistance in primary drying. MTM measurements can be applied to select the optimum shelf temperature, to deter-mine drying end points and to evaluate residual moisture content in secondary drying in real-time. The freeze dryer overload conditions can be estimated by calculation of heat/mass flow at the target product temperature. Therefore, MTM can serve as a powerful Process Analytical Technology for freeze-drying at laboratory and manufacturing scales.
9:20 Scale-Up Considerations and Cycle Development
Stephen Chang, Ph.D., Senior Scientist, MedImmune, Inc.

9:50 Coffee Break in the Exhibit Hall

10:45 Poster Awards in Exhibit Hall

Special In-Depth Presentation

11:00 Root Cause Analysis and Risk Assessment for Lyophilized Product
Edward H. Trappler, President and Founder, Lyophilization Technology, Inc.

The risk of failure and sensitivity to events such as abhorrent conditions, process excursions and differences in dried product attributes sometimes occur in routine manufacturing is high for lyophilized products. Such events warrant an analysis of the root cause and evaluation of any impact on the final product attributes and suitability in releasing a batch. Knowledge of the process and product through appropriate development activities and the ability to assess the impact of such events are critical in evaluating their impact on final product quality.

  • Resources and approaches for proper analysis and impact assessment will be highlighted, and encompass

  • Evaluating data and a scientific rational for critical product characteristics and attributes
  • Identifying and understanding critical and key parameters and their effect on the process
  • Use of real-world examples of root causes and impact on process and product
  • Impact of new indications and dosage forms in "energizing" sales
  • Reallocate resources between internal and external development groups to maximize asset
12:00 A Gentle PAT Approach to In-Line Control of the Lyophilization Process
Miquel Galan, R&D and Innovation Director, IMA-Telstar, S.L.

A lyophilization process is usually only specified in terms of a 乪recipe乫 (shelf temperature and chamber pressure vs. time). This, however, may not guarantee repeatable conditions for the freezing and sublimation steps. According to the recent PAT guidelines, there is the need to study in depth the process in order to develop on-line tools to enable better monitoring and control. It is necessary to move from intensive property (independent of mass) measurements (such as temperature, pressure -partial or total-) to parameters which are scalable and in so doing implement the necessary tools to control the parameters and hence the cycle; thus permitting real-time feedback control actions. Two variables are key to monitoring the lyophilization process: sublimation interface temperature (during the whole of primary drying this has to be maintained below the collapse temperature) and sublimation mass flow (which has to be maximized to achieve the most cost effective cycle). With classical monitoring tools these key goals are not achievable. This is an important issue because:

  • Traditional lyophilization process needs a serious qualitative step to adapt to this emerging PAT guidelines initiative and in depth analysis helps to gain process knowledge
  • From simpler steady state models up to more complex transient ones, they open a window into the process assisting to assess important lyophilization parameters
  • Process can be optimized from the initial R&D
  • R&D stage of process development tremendously simplified (time saving)
  • Industrial processes can be monitored
  • In-line closed loop control possible

Key learning objectives:

  • Hear about new and developing technologies for Process Control
  • Understand how to control product consistency from lab scale to full scale production
  • Discover areas for potential process and operational optimization

12:30 Lunch on Own or Luncheon and Strategic Solutions Presentations

Joint Plenary Keynote Session
LYOPHILIZATION PROTEIN PRODUCTION PROCESS MANAGEMENT

1:45 Chairperson乫s Remarks

1:50 Policy, Regulatory and Engineering Considerations when Transitioning from Lab to Manufacturing Scale

2:20 Vaccines vs. Biologics: Protein Production, Process Management and Lyophilization Considerations
Susan Behrens, Senior Director, Biological Sciences & Strategy, Merck & Co., Inc.

Vaccine production shares many process features with biologics manufacturing. Common unit operations include fermentation, cell culture, chromatography, filtration, formulation, vial & syringe filling and lyophilization. As the demand for vaccine products is projected to increase by 2X over the next 5 years, the ability to transfer knowledge gained from large scale protein production provides an opportunity to maximize efficiency of production for both product areas.

  • Synergies between biologics and vaccine manufacture
  • Vaccines vs. biologics: Distinctive qualities and impact on production, process
    management and lyophilization
  • Key supply chain issues for both vaccines and biologic products and how the
    two interact
  • Leveraging lessons from biologics production as the vaccine business grows globally

3:00 Refreshment Break

Joint Interactive Workshop
DEVELOPING A STREAMLINED MATRIX APPROACH FOR QUALIFICATION AND VALIDATION

3:20 Interactive Case Studies for Matrix Validation Approaches and Challenges for Lyophilized Products
Robert Darius, Director, Global Quality Assurance, GlaxoSmithKline Biologicals

The goal of the program is to address the challenge of whether more data be provided while using less active pharmaceutical product.Whether your product is lyophilized or not, budgetary, timing, validation and regulatory concerns all coalesce during the rapid development and fast track approval processes for pharmaceutical development, scale-up and new CMO approval for pharmaceutical products. These challenges have become increasingly complex in the highly competitive global environment.Through these interactive case scenarios, participants will work in small teams to review scenarios and challenges associated with development, implementation and regulatory approval of matrix validation approaches for lyophilized products. Several different case studies will be provided and group input will allow for in-depth discussion of key points to consider.

  • Reinforcement of basic matrix validation approaches
  • Exposure and use of currently available (and accepted) technologies to assess key physical formulation characteristics
  • Increased understanding of regulatory concerns and requirements
  • Use of different approaches to assess multi-variate challenges in validation
4:00 Interactive Team Project - Sharing Ideas to Develop a MATRIX
Meeting delegates will be given a problem scenario and a set of questions and discussion points. Delegates at each table will review scenarios and challenges associated with development, implementation and regulatory approval of matrix validation approaches. Table moderators will interrogate the issues and facilitate the discussion focused on the group乫s MATRIX design.
Moderators:
Edward H. Trappler, President and Founder, Lyophilization Technology, Inc.
Jeff Schwegman, Ph.D., Founder/Chief Scientific Officer, BioConvergence LLC
Palani Palaniappan, Ph.D., Senior Director, Pharmaceutical Sciences,
Millennium Pharmaceuticals
Robert Darius, Director, Global Quality Assurance, GlaxoSmithKline Biologicals
Narlin Beaty, Ph.D., Managing Partner, Mechanical Engineering, Qualification Process Solutions, LLC

5:00 Closing Comments and Take Home Message


Upstream and Downstream Pipeline Breakthroughs
会议概要 短期研讨会 会议议程 展示者/赞助厂商 地点 询问 报名   Hotel Del Coronado / San Diego, California